Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Leiden University Medical Center: Clinical Trials & FDA Approval Profile

Leiden University Medical Center (Global / Institutional) sponsors 44 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 14 active protocols (10 recruiting now), 7 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)4.5%
Median Closed Enrollment vs National (145 pts)43 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Leiden University Medical Center
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)44
Active Pipeline (Recruiting Now)14 (10)
Completed vs Stopped Early7 / 2 (4.5%)
Median Closed Actual Enrollment43 participants
Physical Hospital Site Disclosure99.5% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Leiden University Medical Center
Hospital Research SiteLocationShared Protocols
Leiden University Medical CenterLeiden31
Erasmus Medical CenterRotterdam7
University Medical Center GroningenGroningen3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Leiden University Medical Center
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05393791Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPCPhase IIRECRUITING
NCT06275958DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal CancerPhase IIIRECRUITING
NCT07018661[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric CancerPhase II/IIIRECRUITING
NCT05255653Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular FeaturesPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Leiden University Medical Center Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI